From the databaseWhat the row says.
Every entry follows the same shape: what is happening, the mechanism, and the recommendation.
Scope
Supplement × Supplement
Last verified
June 4, 2026
CautionEmerging evidence
What is happening. Tangeretin is a recognized inhibitor of cytochrome P450 enzymes (notably CYP1A2 and CYP3A4), and berberine also inhibits CYP3A4 and CYP2D6, so combining them may compound effects on the metabolism of co-administered drugs.
Mechanism. Polymethoxylated flavones such as tangeretin inhibit CYP1A2 and CYP3A4 in the gut and liver; berberine adds CYP3A4 and CYP2D6 inhibition. Combined enzyme inhibition can raise plasma concentrations of certain prescription substrates.
Recommendation. The two supplements together are generally tolerated, but use caution if you also take narrow-therapeutic-index medications metabolized by CYP3A4 or CYP1A2 and consult a clinician or pharmacist.
Stack Score
How it moves the number.
Effect on the composite score
If both Berberine and Tangeretin are in the same stack, this pair applies −5 to your Stack Score (per scored caution row).
The full algorithm, the clamping rules, and four worked stacks are at /methodology/stack-score.
SourcesSources, by evidence tier.
Every claim on this page is cited. PMIDs link straight to PubMed.
Reference material
1- 1Guo Y, et al. Repeated administration of berberine inhibits cytochromes P450 in humans. European Journal of Clinical Pharmacology. 2012.Needs sourceNo link